Cargando…

Dose-Escalated Salvage Radiotherapy for Macroscopic Local Recurrence of Prostate Cancer in the Prostate-Specific Membrane Antigen Positron Emission Tomography Era

SIMPLE SUMMARY: Prostate cancer often relapses after initial radical prostatectomy, and salvage radiotherapy offers a second chance of cure for relapsed patients. Modern imaging techniques, especially prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT),...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamihardja, Jörg, Zehner, Leonie, Hartrampf, Philipp E., Cirsi, Sinan, Wegener, Sonja, Buck, Andreas K., Flentje, Michael, Polat, Bülent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562896/
https://www.ncbi.nlm.nih.gov/pubmed/36230878
http://dx.doi.org/10.3390/cancers14194956
_version_ 1784808279311908864
author Tamihardja, Jörg
Zehner, Leonie
Hartrampf, Philipp E.
Cirsi, Sinan
Wegener, Sonja
Buck, Andreas K.
Flentje, Michael
Polat, Bülent
author_facet Tamihardja, Jörg
Zehner, Leonie
Hartrampf, Philipp E.
Cirsi, Sinan
Wegener, Sonja
Buck, Andreas K.
Flentje, Michael
Polat, Bülent
author_sort Tamihardja, Jörg
collection PubMed
description SIMPLE SUMMARY: Prostate cancer often relapses after initial radical prostatectomy, and salvage radiotherapy offers a second chance of cure for relapsed patients. Modern imaging techniques, especially prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT), enable radiation oncologists to target radiotherapy at the involved sites of disease. In a group of patients, PSMA PET/CT imaging can detect a macroscopic local recurrence with or without locoregional lymph node metastasis. In these cases, an escalation of the radiotherapy dose is often considered for controlling the visible tumor mass. As the evidence for dose-escalated salvage radiotherapy for macroscopic recurrent prostate cancer after PSMA PET/CT imaging is still limited, we address this topic in the current analysis. We found that the outcome of patients with dose-escalated salvage radiotherapy for macroscopic prostate cancer recurrence is encouragingly favorable, while the toxicity is very limited. ABSTRACT: Background: The purpose of this study was to access the oncological outcome of prostate-specific membrane antigen positron emission tomography (PSMA PET/CT)-guided salvage radiotherapy (SRT) for localized macroscopic prostate cancer recurrence. Methods: Between February 2010 and June 2021, 367 patients received SRT after radical prostatectomy. Out of the 367 screened patients, 111 patients were staged by PSMA PET/CT before SRT. A total of 59 out of these 111 (53.2%) patients were treated for PSMA PET-positive macroscopic prostatic fossa recurrence. Dose-escalated SRT was applied with a simultaneous integrated boost at a median prescribed dose of 69.3 Gy (IQR 69.3–72.6 Gy). The oncological outcome was investigated using Kaplan-Meier and Cox regression analyses. The genitourinary (GU)/gastrointestinal (GI) toxicity evaluation utilized Common Toxicity Criteria for Adverse Events (version 5.0). Results: The median follow-up was 38.2 months. The three-year biochemical progression-free survival rate was 89.1% (95% CI: 81.1–97.8%) and the three-year metastasis-free survival rate reached 96.2% (95% CI: 91.2–100.0%). The cumulative three-year late grade 3 GU toxicity rate was 3.4%. No late grade 3 GI toxicity occurred. Conclusions: Dose-escalated PSMA PET/CT-guided salvage radiotherapy for macroscopic prostatic fossa recurrence resulted in favorable survival and toxicity rates.
format Online
Article
Text
id pubmed-9562896
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95628962022-10-15 Dose-Escalated Salvage Radiotherapy for Macroscopic Local Recurrence of Prostate Cancer in the Prostate-Specific Membrane Antigen Positron Emission Tomography Era Tamihardja, Jörg Zehner, Leonie Hartrampf, Philipp E. Cirsi, Sinan Wegener, Sonja Buck, Andreas K. Flentje, Michael Polat, Bülent Cancers (Basel) Article SIMPLE SUMMARY: Prostate cancer often relapses after initial radical prostatectomy, and salvage radiotherapy offers a second chance of cure for relapsed patients. Modern imaging techniques, especially prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT), enable radiation oncologists to target radiotherapy at the involved sites of disease. In a group of patients, PSMA PET/CT imaging can detect a macroscopic local recurrence with or without locoregional lymph node metastasis. In these cases, an escalation of the radiotherapy dose is often considered for controlling the visible tumor mass. As the evidence for dose-escalated salvage radiotherapy for macroscopic recurrent prostate cancer after PSMA PET/CT imaging is still limited, we address this topic in the current analysis. We found that the outcome of patients with dose-escalated salvage radiotherapy for macroscopic prostate cancer recurrence is encouragingly favorable, while the toxicity is very limited. ABSTRACT: Background: The purpose of this study was to access the oncological outcome of prostate-specific membrane antigen positron emission tomography (PSMA PET/CT)-guided salvage radiotherapy (SRT) for localized macroscopic prostate cancer recurrence. Methods: Between February 2010 and June 2021, 367 patients received SRT after radical prostatectomy. Out of the 367 screened patients, 111 patients were staged by PSMA PET/CT before SRT. A total of 59 out of these 111 (53.2%) patients were treated for PSMA PET-positive macroscopic prostatic fossa recurrence. Dose-escalated SRT was applied with a simultaneous integrated boost at a median prescribed dose of 69.3 Gy (IQR 69.3–72.6 Gy). The oncological outcome was investigated using Kaplan-Meier and Cox regression analyses. The genitourinary (GU)/gastrointestinal (GI) toxicity evaluation utilized Common Toxicity Criteria for Adverse Events (version 5.0). Results: The median follow-up was 38.2 months. The three-year biochemical progression-free survival rate was 89.1% (95% CI: 81.1–97.8%) and the three-year metastasis-free survival rate reached 96.2% (95% CI: 91.2–100.0%). The cumulative three-year late grade 3 GU toxicity rate was 3.4%. No late grade 3 GI toxicity occurred. Conclusions: Dose-escalated PSMA PET/CT-guided salvage radiotherapy for macroscopic prostatic fossa recurrence resulted in favorable survival and toxicity rates. MDPI 2022-10-10 /pmc/articles/PMC9562896/ /pubmed/36230878 http://dx.doi.org/10.3390/cancers14194956 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tamihardja, Jörg
Zehner, Leonie
Hartrampf, Philipp E.
Cirsi, Sinan
Wegener, Sonja
Buck, Andreas K.
Flentje, Michael
Polat, Bülent
Dose-Escalated Salvage Radiotherapy for Macroscopic Local Recurrence of Prostate Cancer in the Prostate-Specific Membrane Antigen Positron Emission Tomography Era
title Dose-Escalated Salvage Radiotherapy for Macroscopic Local Recurrence of Prostate Cancer in the Prostate-Specific Membrane Antigen Positron Emission Tomography Era
title_full Dose-Escalated Salvage Radiotherapy for Macroscopic Local Recurrence of Prostate Cancer in the Prostate-Specific Membrane Antigen Positron Emission Tomography Era
title_fullStr Dose-Escalated Salvage Radiotherapy for Macroscopic Local Recurrence of Prostate Cancer in the Prostate-Specific Membrane Antigen Positron Emission Tomography Era
title_full_unstemmed Dose-Escalated Salvage Radiotherapy for Macroscopic Local Recurrence of Prostate Cancer in the Prostate-Specific Membrane Antigen Positron Emission Tomography Era
title_short Dose-Escalated Salvage Radiotherapy for Macroscopic Local Recurrence of Prostate Cancer in the Prostate-Specific Membrane Antigen Positron Emission Tomography Era
title_sort dose-escalated salvage radiotherapy for macroscopic local recurrence of prostate cancer in the prostate-specific membrane antigen positron emission tomography era
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562896/
https://www.ncbi.nlm.nih.gov/pubmed/36230878
http://dx.doi.org/10.3390/cancers14194956
work_keys_str_mv AT tamihardjajorg doseescalatedsalvageradiotherapyformacroscopiclocalrecurrenceofprostatecancerintheprostatespecificmembraneantigenpositronemissiontomographyera
AT zehnerleonie doseescalatedsalvageradiotherapyformacroscopiclocalrecurrenceofprostatecancerintheprostatespecificmembraneantigenpositronemissiontomographyera
AT hartrampfphilippe doseescalatedsalvageradiotherapyformacroscopiclocalrecurrenceofprostatecancerintheprostatespecificmembraneantigenpositronemissiontomographyera
AT cirsisinan doseescalatedsalvageradiotherapyformacroscopiclocalrecurrenceofprostatecancerintheprostatespecificmembraneantigenpositronemissiontomographyera
AT wegenersonja doseescalatedsalvageradiotherapyformacroscopiclocalrecurrenceofprostatecancerintheprostatespecificmembraneantigenpositronemissiontomographyera
AT buckandreask doseescalatedsalvageradiotherapyformacroscopiclocalrecurrenceofprostatecancerintheprostatespecificmembraneantigenpositronemissiontomographyera
AT flentjemichael doseescalatedsalvageradiotherapyformacroscopiclocalrecurrenceofprostatecancerintheprostatespecificmembraneantigenpositronemissiontomographyera
AT polatbulent doseescalatedsalvageradiotherapyformacroscopiclocalrecurrenceofprostatecancerintheprostatespecificmembraneantigenpositronemissiontomographyera